3DBio Therapeutics Overview

  • Founded

  • 2014

Founded
  • Status

  • Private

  • Employees

  • 50

Employees
  • Latest Deal Type

  • Series A

  • Latest Deal Amount

  • $21M

  • Investors

  • 8

3DBio Therapeutics General Information

Description

Developer of a 3D-bioprinting and material technology designed to treat disease and congenital medical conditions. The company's technologies focus on regenerative medicine solving medical challenges with custom-engineered 3D-printed living transplants, also develops living tissue implants with structural and functional integrity with a four-part technology platform, including novel and proprietary 3D-bioprinter, bio-ink, specialized cell culture system and implantable protective shell, enabling healthcare professionals to get access to safe and functional implant technologies delivering optimal patient outcomes.

Contact Information

Website
www.3dbiocorp.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 51-36 35th Street
  • Long Island City
  • New York, NY 11101
  • United States
+1 (212) 000-0000

3DBio Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

3DBio Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series A) 29-Apr-2022 $21M 000.00 000.00 Completed Clinical Trials - Phase 2
1. Later Stage VC (Series A) 10-Apr-2019 00.000 00.000 000.00 Completed Pre-Clinical Trials
To view 3DBio Therapeutics’s complete valuation and funding history, request access »

3DBio Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view 3DBio Therapeutics’s complete cap table history, request access »

3DBio Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a 3D-bioprinting and material technology designed to treat disease and congenital medical conditions. The c
Therapeutic Devices
New York, NY
50 As of 2022
000.00
00.00 0000-00-00
00000000000 000.00

000000

giat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deser
00000 0000000000 0000000000 0000000
San Francisco, CA
00 As of 0000
000.00
0000 0000-00-00
00000000000 000.00

000000

cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culp
00000 0000000 000 00000000
San Francisco, CA
0 As of 0000
00.000
000000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

3DBio Therapeutics Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Prellis Biologics Venture Capital-Backed San Francisco, CA 00 000.00 00000000000 000.00
00000000 000 Venture Capital-Backed San Francisco, CA 0 00.000 000000000000 00.000
00000 00000000000 Venture Capital-Backed Madison, WI 00 000.00 0000000000 0 000.00
000000 0000000000 Venture Capital-Backed Vancouver, Canada 00 000.00 00000000000 000.00
00000000 Formerly VC-backed Schlieren, Switzerland 00 000.00 000000000 000.00
To view 3DBio Therapeutics’s complete competitors history, request access »

3DBio Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Hod Lipson Ph.D Co-Founder
Larry Bonassar Ph.D Co-Founder
Daniel Cohen Ph.D Co-Founder, Chief Executive Officer and Board Member
Colin McDonough Chief Financial Officer
Nathaniel Bachrach Ph.D Chief Scientific Officer & Executive Vice President
You’re viewing 5 of 8 executive team members. Get the full list »

3DBio Therapeutics Board Members (6)

Name Representing Role Since
Harlan Weisman MD Self Chairman 000 0000
Kevin Slawin MD Self Board Member 000 0000
Matthew Fitzpatrick 3DBio Therapeutics Board Member 000 0000
Michael Bator Self Board Member 000 0000
Scott Dylla Ph.D 3DBio Therapeutics Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

3DBio Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

3DBio Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Expa Venture Capital Minority 000 0000 000000 0
Vision Capital Group Hedge Fund Minority 000 0000 000000 0
Blue Collective Venture Capital Minority 000 0000 000000 0
Hibiscus Capital Management Venture Capital Minority 000 0000 000000 0
Kairos Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial